Teva FY2024 revenue $16.5B, GAAP EPS loss $1.45; non-GAAP EPS $2.49; sees 2025 rev $16.8-17.4B

TEVA PHARMACEUTICAL INDUSTRIES LTD

2024-FY EPS reported -$1.45 revenue$16,544,000,000

FY2024 revenues $16.5B, +4% USD (+6% local currency); GAAP net loss $1.639B ($1.45/share) vs $559M loss in FY2023.
Non-GAAP diluted EPS $2.49, down from $2.56; adjusted EBITDA $4.78B.
Key product revenues: AUSTEDO >$1.6B, AJOVY $507M (+18% local), UZEDY $117M.
Generics grew 15% in U.S., 6% in Europe, 15% in International Markets (local currency).
FY2025 outlook: revenue $16.8-$17.4B, non-GAAP EPS $2.35-$2.65, free cash flow $1.6-$1.9B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.